LYNX1 CAPITAL MANAGEMENT LP
Q2 2024 Form 13-F
SAN JUAN, PUERTO RICO
CIK 0001910456
· CRD 310301
· SEC-registered investment adviser
Consolidated report · includes
1 manager
since Q4 2021
$277.2M Reported Value Total
LYNX1 CAPITAL MANAGEMENT LP reports 4 total accounts under management (AUM). There are 4 discretionary accounts valued at $268,343,489, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered
Discretionary Manager
Private funds (Form ADV)
2 funds
· $576.8M gross asset value
Hedge Fund: $576.8M · Private Equity Fund: $0
Source: Form ADV filed 2026-11-04
Reported value
$277.2M
Quarter over quarter
-8.6%
Holdings
17
Top-10 concentration
98.9%
Filing Structure
Reports holdings for
- Lynx1 Capital Advisors LLC · File #028-22145 · since Q4 2021
Key People
Form ADV owners & control persons
Weston Agnew Nichols
CHIEF INVESTMENT OFFICER, LIMITED PARTNER
Michael Neddal Barakat
CHIEF COMPLIANCE OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q2 2024 13F record
Q2 2024 13F filing summary
| Period of report | June 30, 2024 |
|---|---|
| Filed | August 14, 2024 |
| Form | 13F-HR |
| Reported value | $277.2M |
| Positions | 17 |
| Change in reported value | -28.6% |
| New positions | 7 |
| Exited positions | 6 |
| Position turnover | 56.5% |
| Top-10 concentration | 98.9% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 12, 2026
|
27 | $865.5M |
|
Q1 2026 13F
Filed May 4, 2026
|
23 | $632.7M |
|
Q4 2025 13F
Filed Feb 17, 2026
|
22 | $494.0M |
|
Q3 2025 13F
Filed Nov 13, 2025
|
14 | $491.3M |
|
Q2 2025 13F
Filed Aug 14, 2025
|
15 | $346.2M |
|
Q1 2025 13F
Filed May 15, 2025
|
14 | $279.2M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
18 | $266.7M |
|
Q3 2024 13F
Filed Nov 14, 2024
|
18 | $282.2M |
|
Q2 2024 13F
Filed Aug 14, 2024
|
17 | $277.2M |
|
Q1 2024 13F
Filed May 15, 2024
|
16 | $388.2M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
15 | $254.3M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
18 | $151.2M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
18 | $152.6M |
|
Q1 2023 13F
Filed May 15, 2023
|
13 | $119.9M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
13 | $115.6M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
12 | $110.9M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
12 | $117.4M |
|
Q1 2022 13F
Filed May 16, 2022
|
14 | $107.7M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
10 | $114.6M |
Top 17 holdings · Q2 2024
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | MRUS MERUS N V | $71.4M | 25.76% |
| 2 | STOK STOKE THERAPEUTICS INC | $70.1M | 25.27% |
| 3 | GHRS GH RESEARCH PLC | $46.3M | 16.69% |
| 4 | CCCC C4 THERAPEUTICS INC | $31.8M | 11.47% |
| 5 | TCRX TSCAN THERAPEUTICS INC | $30.6M | 11.03% |
| 6 | CGEM CULLINAN THERAPEUTICS INC | $6.6M | 2.37% |
| 7 | ALLO ALLOGENE THERAPEUTICS INC | $5.2M | 1.87% |
| 8 | LBPH LONGBOARD PHARMACEUTICALS IN | $4.5M | 1.63% |
| 9 | PASG PASSAGE BIO INC | $4.0M | 1.45% |
| 10 | CABA CABALETTA BIO INC | $3.7M | 1.33% |
| 11 | IBIO IBIO INC | $1.8M | 0.64% |
| 12 | BNOX BIONOMICS LIMITED | $459.9K | 0.17% |
| 13 | PIRS PIERIS PHARMACEUTICALS INC | $426.8K | 0.15% |
| 14 | KNSA KINIKSA PHARMACEUTICALS INTL | $177.4K | 0.06% |
| 15 | CNTA CENTESSA PHARMACEUTICALS PLC | $157.1K | 0.06% |
| 16 | KRRO KORRO BIO INC | $128.7K | 0.05% |
| 17 | VYNE VYNE THERAPEUTICS INC | $31.9K | 0.01% |
Values as reported on the Q2 2024 Form 13F. Every position is in the holdings table below.